News|Videos|November 18, 2026

Upadacitinib Tied to Durable RA Response, With Louis Bessette, MD, MSc

Fact checked by: Alex Hillenbrand

Pooled UPHOLD and CLOSE-UP data from 2111 patients show 63.1% remained on upadacitinib at 24 months, with no new safety signals.

Nearly half of patients with moderate to severe rheumatoid arthritis (RA) who started upadacitinib (Rinvoq) in routine practice reached remission on the 28-joint Disease Activity Score using C-reactive protein (DAS28[CRP]) by month 3. Responses held through 2 years in a pooled real world analysis.¹

Louis Bessette, MD, MSc, a rheumatologist in Quebec City and professor at Laval University, presented the integrated UPHOLD and CLOSE-UP results at the American College of Rheumatology (ACR) Convergence 2026 in Orlando, Florida. In an interview with HCPLive, he said the combined cohort, which he described as the largest observational post-marketing study of upadacitinib in RA, reflects the patients rheumatologists treat every day, most of whom would not be eligible for a randomized trial.

Real World Upadacitinib Evidence Beyond the SELECT Trials

Upadacitinib is an oral, Janus kinase 1 (JAK1) selective inhibitor. It showed efficacy and safety in moderate to severe RA across the SELECT phase 3 program. Trial populations can differ from routine practice in comorbidities, prior treatment, and how long patients stay on therapy.¹

Each study had reported on its own before this analysis. In UPHOLD, responses reached at 6 months were maintained through 2 years with no new safety findings.² In the Canadian CLOSE-UP study, 60.7% of patients reached the primary endpoint of DAS28(CRP) <2.6 at 6 months.³ Investigators pooled the 2 cohorts to get a larger sample for analysis.

UPHOLD and CLOSE-UP Pooled Cohort Design

UPHOLD is a multicountry study conducted outside the US, and CLOSE-UP was run at sites across Canada. Both enrolled adults with moderate to severe RA starting upadacitinib 15 mg once daily. Investigators assessed DAS28(CRP) and Clinical Disease Activity Index (CDAI) targets at baseline and at months 3, 6, 12, and 24.¹

Patient-reported outcomes included the minimal clinically important difference (MCID) in the Health Assessment Questionnaire Disability Index (HAQ-DI ≥0.22) and in the Functional Assessment of Chronic Illness Therapy Fatigue scale (FACIT-Fatigue ≥3.56), plus ≥50% improvement in pain. Effectiveness was reported as observed, without imputation for patients who stopped treatment. Safety was reported as exposure-adjusted incidence rates per 100 patient-years.¹

The pooled population included 2111 patients: 1699 from UPHOLD and 412 from CLOSE-UP. Overall, 79.6% were female, the mean age was 57.5 years, and the mean baseline DAS28(CRP) was 4.5, which indicates moderate disease activity.¹ At month 24, 1,331 patients (63.1%) were still taking upadacitinib. Bessette said this persistence is notable because many patients in the cohort had already failed biologic or targeted synthetic therapies and were harder to treat.

DAS28 and CDAI Remission With Upadacitinib Through 24 Months

At month 3, 48.0% of patients had DAS28(CRP) <2.6 and 64.6% had DAS28(CRP) ≤3.2. Among patients still taking upadacitinib at month 24, those rates were 68.9% and 82.6%.¹

CDAI targets were reached less often. At month 3, 17.3% of patients reached CDAI remission (≤2.8) and 53.0% reached low disease activity (≤10). By month 24, those rates were 36.4% and 76.3%.¹

“It’s much more difficult to achieve remission defined by the CDAI,” Bessette said. “I think for clinicians, CDAI is a little bit more important because it does not include the CRP that may be influenced by a JAK1 inhibitor. With DAS28, you may still have swollen joints, sometimes 4 or 5 swollen joints, and the patient will be in low disease activity or remission.”

He said reporting both measures still matters, because many randomized trials have used DAS28 as their main measure of disease activity.

Function, Fatigue, and Pain Outcomes in Rheumatoid Arthritis

Patient-reported outcomes improved early. At month 3, 58.5% of patients met the HAQ-DI MCID, 59.5% met the FACIT-Fatigue MCID, and 45.9% had ≥50% improvement in pain. Response rates kept rising through month 24 among patients who stayed on treatment.¹

“Patients don’t care about their swollen joint count,” Bessette said. “They care about how they can function and, you know, can they have a normal life.”

Upadacitinib Safety and Herpes Zoster Vaccination

The safety profile matched the SELECT program, and no new safety risks were identified.¹ Bessette cautioned that 24 months of follow-up is still limited for rare events, which take time to appear.

He noted that herpes zoster vaccination rates differed between the cohorts and attributed this mainly to access. In his province, the vaccine is free for all patients.

“I think that all our patients should be vaccinated when they go on advanced therapy,” Bessette said. “But the main barrier is the access and having free vaccination for the patient.”

Because the effectiveness data were analyzed as observed, the month 24 response rates reflect patients who stayed on upadacitinib. Bessette also said a separate CLOSE-UP analysis, recently accepted for publication, found similar response rates whether patients were biologic naive or had failed earlier biologic or targeted synthetic therapy, and whether they took upadacitinib alone or with methotrexate.

Editor’s Note: Bessette reports relevant disclosures with AbbVie.

References
  1. Bessette L, Mysler E, Attar S, et al. Real-World Effectiveness of Upadacitinib in Rheumatoid Arthritis: 24-Month Integrated Results From the UPHOLD and CLOSE-UP Post-Marketing Observational Studies. Abstract presented at: American College of Rheumatology (ACR) Convergence 2026; November 6–11, 2026; Orlando, FL. Abstract 1419.
  2. Östör A, Feist E, Sidiropoulos P, et al. Achievement and Maintenance of Disease Targets with Upadacitinib in Rheumatoid Arthritis: 2-Year Outcomes from the UPHOLD Real-World Study. Rheumatol Ther. 2026;13:659-676. doi:10.1007/s40744-026-00826-5
  3. Bessette L, Chow A, Rai R, et al. Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in Canadian Real-World Practice: Final Results from the CLOSE-UP Post-Marketing Observational Study. J Rheumatol. 2026;53(Suppl 1):50-51. doi:10.3899/jrheum.2026-0447.9

Related to this article